PDF Cover

Immunoassay Analyzers Market

The market for Immunoassay Analyzers was estimated at $8.0 billion in 2025; it is anticipated to increase to $10.3 billion by 2030, with projections indicating growth to around $13.3 billion by 2035.

Report ID:DS1801050
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Immunoassay Analyzers
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Immunoassay Analyzers Market Outlook

Revenue, 2025

$8.0B

Forecast, 2035

$13.3B

CAGR, 2026 - 2035

5.3%

The Immunoassay Analyzers industry revenue is expected to be around $8.0 billion in 2026 and expected to showcase growth with 5.3% CAGR between 2026 and 2035. Automated immunoassay systems are now a vital component in the global in vitro diagnostics sector with this positive outlook indicating the extent to which Immunoassay Analyzers are used. Healthcare providers depend on these systems for the prompt and precise detection of biomarkers in order to make informed decisions. The main drivers of demand are the rising incidence of cancer and of infectious diseases, the latter and former combining to make up 67.5% of the market demand. This high demand is because of the need for treatments, for monitoring and for screening. Sales of benchtop immunoassay analysers totalled $5.78 billion last year with their popularity boosted by their suitability for laboratories and near patient testing and their compact size which enables easy integration into automated laboratory workflows in various care settings.

Immunoassays are sophisticated diagnostic equipment used to test for a variety of substances, including the antigen antibody reaction which can be facilitated by either ELISA or chemiluminescent immunoassay, providing accurate results. The equipment allows laboratories to easily manage large amounts of tests through high throughput screening capabilities, a variety of assay tests, simple to use software and the ability to interface with a laboratorys computer system. Examples of current applications include infectious disease, cancer monitoring, cardiology, endocrinology and the monitoring of medicinal drugs, with current developments in region's such as portable analyser equipment, multi test assays and diagnostic devices situated at the point of treatment. The clinical utility of Immunoassay analysers is being increased by the on going development of Immunoassay analysers, the automation of Immunoassay analysers and data analysis techniques. These factors are ensuring that Immunoassay analysers remain the cornerstone of in vitro diagnostics today.

Immunoassay Analyzers market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Immunoassay Analyzers Market Outlook

Market Key Insights

  • The Immunoassay Analyzers market is projected to grow from $8.0 billion in 2025 to $13.3 billion in 2035. This represents a CAGR of 5.3%, reflecting rising demand across Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes.

  • This market is dominated by major players including Siemens Healthineers AG, Abbott and Ortho Clinical Diagnostics.

  • The US and Germany are the largest markets in the immunoassay analyzers sector. These markets are expected to grow at a rate between 3.4% and 5.1% per annum from 2025.

  • China, Brazil and India are predicted to have the fastest growth with compound annual growth rates ranging from 6.1% to 7.3%.

  • Digital transformation is likely to have a major impact on the value chain of the immunoassay analyser market in both the US and Germany. By 2030, it should be worth approximately $265 million on top of the Immunoassay Analyser market.

  • Over the period of 2025 to 2035, the Immunoassay Analyzers sector is due to add $5.4 billion in value. Growth is expected to come from those businesses who produce equipment which is used for cardiology and oncology.

  • With

    rising chronic disease burden and laboratory automation adoption across diagnostic ecosystems, and

    Technological advances in assay sensitivity and multiplexing capabilities, Immunoassay Analyzers market to expand 68% between 2025 and 2035.

immunoassay analyzers market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Immunoassay Analyzers - Country Share Analysis

Opportunities in the Immunoassay Analyzers

Growing use of healthcare services over the internet is also at the moment encouraging the rollout of point of care testing in pharmacies and other community clinics. Portable immunoassay analyzers for cardiac markers, infectious diseases and drug monitoring are set to grow at a compound annual growth rate of 6.1% over the next five years, from $2.18 billion in 2025 to $2.93 billion by 2030. The devices that can be connected to a network and which are used in conjunction with electronic health records as well as cloud computing are likely to be most popular in retail clinic chains and primary care clinics.

Growth Opportunities in North America and Asia-Pacific

The adoption of immunoassay analyzers in North America is primarily driven by the hospitals with high test volumes in their in house laboratories. Additionally, hospitals are adopting automated immunoassay systems capable of testing on demand. This is mainly due to a well established clinical diagnostics system in the region. Applications for oncology immunoassays are likely to be highly significant, due to the factors of a high cancer incidence rate, stringent screening procedures and strong reimbursement rates for sensitive tumour markers and for companion diagnostic tools in cardiology and endocrinology. Key region's of focus lie in the development of high volume testing systems which offer sophisticated chemiluminescence immunoassays, a streamlined menu and good connectivity with laboratory information systems for hospital laboratories and other large health care organisations. The competitive intensity in this market is escalating, with large scale manufacturers trying to differentiate themselves by introducing innovative assays, offering faster analysis turnaround times and other service agreements that add value. Smaller regional companies focus on niche products and low to mid volume labs in order to avoid direct price competition. The regions market is driven by the need to adhere to strict regulations, the need to automate processes due to staff shortages and the need for analyzers that can produce data that can be used in analytics, particularly in cancer treatment and in managing complex long term health conditions.
The Asia Pacific market for immunoassay analyzers is driven by an increase in the availability of healthcare, by government organised screening programs and the growing need for clinical diagnostic equipment in urban and secondary care hospitals. Given the regions high incidence of infectious diseases and the emphasis placed on monitoring, the region is poised for major growth in the infectious disease region. There will also be significant growth in endocrinology and cardiology testing due to the regions increasing chronic disease burden. The development of cost effective and dependable automated immunoassay systems with the capability to be scaled up represents a prime region for growth. A good illustration of this is mid range technology and compact devices which can be deployed in region's where resources are limited. These instruments still produce robust chemiluminescent immunoassay results. The market for biological kits is characterised by a mix of small, local companies which are growing rapidly and multinational firms. Competition is increasing from local companies who are capable of competing on the price of their products, on service which is tailored to a region and on the price of the reagents used. Factors which are likely to drive demand in this market are a rise in the healthcare infrastructure, an increase in private laboratory networks, the growing awareness of the need for early diagnosis and the growing use of Immunoassay Analyzers. These Immunoassay Analyzers allow laboratories which are centralised to be connected to those which are decentralised or near patients across the Asia Pacific region.

Market Dynamics and Supply Chain

01

Driver: Rising chronic disease burden and laboratory automation adoption across diagnostic ecosystems

The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions is also steadily increasing demand for reliable immunoassay testing. These conditions require frequent monitoring of biomarkers, driving higher test volumes in hospitals and reference laboratories. Parallel to this, laboratories are also accelerating automation adoption to manage workload pressure, reduce manual errors, and improve turnaround times. Advanced immunoassay analyzers with integrated sample handling, onboard quality control, and connectivity to laboratory information systems are also becoming essential. Automation also supports consolidation of testing into centralized labs, especially in emerging markets. Together, disease driven testing demand and automation focused efficiency gains are also reinforcing sustained investment in high throughput, scalable immunoassay analyzer platforms worldwide.
Continuous improvements in assay chemistry, detection optics, and signal amplification are also enhancing the sensitivity and specificity of immunoassay analyzers. Modern systems increasingly support multiplex testing, enabling simultaneous measurement of multiple biomarkers from a single sample. This trend is also particularly important in oncology and infectious disease diagnostics, where comprehensive panels improve clinical decision making. Vendors that integrate multiplexing without sacrificing throughput or accuracy are also gaining competitive advantage and stimulating replacement demand.
02

Restraint: High capital costs and complex validation requirements limiting broader laboratory adoption

Immunoassay analyzers often involve high upfront investment, along with recurring costs for reagents and maintenance. For smaller laboratories and academic centers, these expenses can delay purchasing decisions. Validation and compliance requirements, similar to challenges seen in CRISPR And Cas Genes commercialization, further extend deployment timelines. As a result, revenue growth can be uneven across regions, with demand concentrated among well funded institutions and centralized labs.
03

Opportunity: Infectious disease diagnostics expansion in India and Southeast Asia using Immunoassay Analyzers and High-throughput oncology and drug monitoring in developed healthcare system reference laboratories worldwide

In India and Southeast Asia many hospitals which are public and also private are in the process of expanding diagnostic processes in the clinical field, but one instrument that has seen little use is the automated immunoassay analyser in cities beyond the first tier. Rapid increases in demand for laboratory developed testing for infectious diseases, HIV, hepatitis and cancer biomarkers is presently outstripping central lab infrastructure. Benchtop immunoassay systems which can be automated, designed for low maintenance and high humidity environments, offer the greatest growth potential. This potential is increased through training of laboratory staff in emerging markets, partnerships with distributors and reagent rental schemes.
These are increasing calls for reference and commercial laboratories to develop more standardized, high throughput immunoassay work flows due to the greater complexity of oncology biomarkers and the rising use of biologic based treatments. The market for benchtop chemiluminescent immunoassay analyzers is expected to rise with the use of automation technology in laboratory settings. Benchtop analyser sales are projected to rise from 5.78 billion in 2025 to 7.37 billion by 2030 at a compound annual growth rate of 4.99 %. Pharmaceutical companies and hospital networks will be favourably disposed towards analysers that offer a range of tests and high standards of quality control.
04

Challenge: Regulatory scrutiny and assay standardization challenges affecting market scalability

Stringent regulatory pathways and assay standardization issues continue to restrain market expansion. Variability in regulatory expectations across regions increases development and approval costs, echoing constraints observed in CRISPR And Cas Genes markets. Inconsistent assay harmonization can limit cross platform comparability, affecting customer confidence. These factors slow new product launches, influence procurement cycles, and can dampen near term demand despite strong underlying clinical need.

Supply Chain Landscape

1

Reagent Components

Thermo Fisher ScientificMerck KGaADanaher
2

Immunoassay Analyzers

Roche DiagnosticsAbbottSiemens Healthineers AG
3

IVD Distribution

Cardinal HealthMcKessonHenry Schein
4

Clinical Diagnostics

HospitalsClinical diagnostic laboratoriesResearch institutes
Immunoassay Analyzers - Supply Chain

Use Cases of Immunoassay Analyzers in Clinical Diagnostics & Academic

Clinical Diagnostics : In routine clinical diagnostics, fully automated chemiluminescence immunoassay analyzers are most widely used by hospitals and reference laboratories to deliver high throughput testing for infectious diseases, oncology markers, hormones, and cardiac biomarkers. These systems offer fast turnaround, high sensitivity, and standardized workflows that support large patient volumes. Abbott, Roche Diagnostics, and Siemens Healthineers dominate this space, leveraging broad test menus, strong global service networks, and continuous assay innovation that reinforces their leadership in core diagnostic laboratories.
Pharmaceutical and Biotechnology Companies : Within pharmaceutical and biotechnology companies, benchtop and modular immunoassay analyzers based on ELISA and fluorescent immunoassays detection are primarily used for biomarker validation, pharmacokinetic studies, and immunogenicity testing. These platforms support flexible assay development and precise quantification during drug discovery and clinical trials. Thermo Fisher Scientific, Agilent Technologies, and Bio Rad hold strong positions due to robust research grade systems, reagent compatibility, and integration with upstream analytical workflows critical for regulated drug development environments.
Academic and Research Institutes : Academic and research institutes mainly rely on semi automated ELISA and multiplex immunoassay analyzers to support exploratory studies in immunology, proteomics, and translational research. These systems are valued for flexibility, cost efficiency, and adaptability to novel assays. Bio Rad, Merck Millipore, and Luminex are prominent suppliers, offering versatile platforms, open reagent ecosystems, and strong technical support. Their strengths enable researchers to rapidly customize assays and publish reproducible data across diverse biomedical applications.

Recent Developments

Recent developments in immunoassay analyzers emphasize enhanced automation, expanded biomarker testing panels, and improved assay sensitivity. Clinical laboratories increasingly adopt high-throughput chemiluminescence and multiplex platforms to support rapid infectious disease and oncology diagnostics. A key market trend is the shift toward connectivity and digital integration, enabling seamless data flow with laboratory information systems and remote monitoring. Leading vendors focus on scalable systems, reagent consistency, and point-of-care immunoassay solutions, strengthening competitive positioning in both centralized and decentralized testing environments.

August 2025 : QuidelOrtho Corporation launched a Certified Analyzer Program in the U.S. to expand access to high-quality VITROS™ immunodiagnostic systems for rural hospitals and small labs, enhancing utilization of immunoassay analyzers through refurbishment, certification, and service support.
January 2025 : Abbott received FDA clearance for a new immunoassay test on its Alinity i analyzer, expanding its diagnostic test menu and boosting immunoassay testing capabilities in U.S. clinical laboratories.
April 2024 : Siemens Healthineers launched the Atellica CI Analyzer with FDA clearance, a compact immunoassay and clinical chemistry system designed to improve workflow efficiency for low- to mid-volume labs, broadening its immunoassay analyzer portfolio.

Impact of Industry Transitions on the Immunoassay Analyzers Market

As a core segment of the Medical Device industry, the Immunoassay Analyzers market develops in line with broader industry shifts. Over recent years, transitions such as Digital Transformation in Immunoassay Analyzers and Expansion into decentralized testing environments have redefined priorities across the Medical Device sector, influencing how the Immunoassay Analyzers market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Digital Transformation in Immunoassay Analyzers

The immunoassay analyser industry is seeing its main expansion driver move towards digital transformation, where clinical procedures and the creation of value throughout the supply chain are altered by diagnostic techniques aided by AI and by software analytics. Automated immunoassay analysers are seeing a significant rise in the US and Germany, places where integration with connected hospital IT systems, digital pathology and laboratory automation is significantly reducing turnaround times and clinical diagnostics accuracy. The trend towards the development of sophisticated, automated immunoassay equipment is expected to enhance testing efficiency in both high volume laboratories and medical facilities where patients are tested on site. This is predicted to lead to an increase of approximately $265 million in annual revenue for the industry by 2030. Organisations that are the first to integrate AI, predictive maintenance and remote monitoring in their immunoassay analyzers will reap significant benefits from the growing diagnostics markets. They will set new standards in patient care and diagnostic efficiency.
02

Expansion into decentralized testing environments

Another major transition is the expansion of immunoassay analyzers into decentralized and near patient testing environments. Compact, user friendly systems are being developed for smaller hospitals, specialty clinics, and research settings. This evolution supports faster clinical decisions and reduces dependence on centralized labs. It also influences reagent manufacturing, logistics, and digital connectivity markets, as suppliers adapt products for flexible deployment while maintaining analytical performance comparable to core laboratory systems.